USPTO 2015–2025 USPTO PatentsView US Corporation

Renu Therapy, LLC

USPTO PatentsView assignee record - 14 granted patents across 0 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength.

RSS updates for this company

The verdict

According to USPTO PatentsView, Renu ranks #20,315 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 0 technology areas.

#20,315
of 49,997 US assignees by volume
33rd percentile
by Innovation Score (29.9/100)
1.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R20315 · US Corporation #20,315 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-UNK · INNOV-THIN · CLAIMS-SPARSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 14 grants
  • MID-PACK #20,315/49,997
  • PHOTO-FINISH Rebate Assets
  • CPC-UNK CPC blank
  • INNOV-THIN 29.9/100
  • CLAIMS-SPARSE 1.0 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 8/10 fields

Nearest grant-volume peer: Rebate Assets, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Renu’s 29.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Renu

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Renu's Innovation Score is 29.9/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Renu?

Each dot is one of Renu’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Renu’s own 1.0 claims/patent is at or below the 17.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Renu vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 13.913.91414.1 010203040 Granted patents (volume) Avg claims / patent Rebate Assets, LLC - 14, 5.71Rebate AssetsRedMed Limited - 14, 29.43RedmedRegina Miracle International (Group) Limited - 14, 16.71Regina Miracle In…Relativity Space, Inc. - 14, 17.64Relativity SpaceResense GmbH - 14, 19.5ResenseResnENT, LLC - 14, 21.93ResnentResonance Technology, Inc. - 14, 19Resonance Technol…Respicardia, Inc. - 14, 15.29RespicardiaRenu Therapy, LLC - 14, 1Renu Therapy
Renu vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Renu's grants concentrate

Renu Therapy, LLC is a focused PatentsView assignee: 0 CPC subclasses . Peak complete grant year is 2024 (7 grants) versus a trough of 1 in 2021. By volume, Renu sits between Rebate Assets, LLC and Respicardia, Inc..

Renu's three-year grant acceleration

Renu Therapy, LLC shows 9 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Renu's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Renu holds 14 patents at rank #20,329, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Renu

By rank, the assignees closest to #20,329 in granted patent volume.

Renu's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 33rd percentile higher than 33% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

02468 2021202320242025 4
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Renu Therapy, LLC patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 7.1%
2023 2 14.3%
2024 7 50.0%
2025partial year 4 28.6%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Renu Therapy, LLC's patent record in context - here's where to go next.

  • Ranked #20,315 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Renu Therapy, LLC against Rebate Assets, LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 29.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.